Nanosonics Limited (OQS) AI Stock Analysis
Nanosonics Limited
(Frankfurt:OQS)
No summary available
Nanosonics Limited (OQS) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 550.47M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 51.4
- Beta (1Y)
- 0.18
- Revenue Growth
- 0.36%
- EPS Growth
- -15.56%
- Country
- Germany
- Employees
- 508
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Nanosonics Limited Business Overview & Revenue Model
Company Description
Nanosonics Limited, along with its subsidiaries, functions as a global infection prevention enterprise with operations in Australia and beyond. The company focuses on the production and distribution of its trophon ultrasound probe disinfection system...
Nanosonics Limited Earnings Call Summary
The call presents a predominantly positive operational and financial picture: constant-currency revenue and EBIT growth, strong trophon profitability and cash generation, record placements and upgrades, product innovation (trophon3/trophon2 Plus), solid annuity and service growth, a debt-free balance sheet with substantial cash and an active buyback. Management also delivered substantial regulatory and commercial progress for CORIS and set explicit FY'27 guidance that anticipates continued growth. Negative items are present but largely manageable and/or transitional: a Q3 consumables dip due to weather, margin moderation from product mix and currency, APAC softness tied to rental models, and elevated near-term OpEx to fund CORIS commercialization which will weigh on near-term profitability. Overall, highlights substantially outweigh the lowlights, with CORIS viewed as a meaningful long-term growth opportunity while trophon continues as a strong cash engine.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided FY'27 constant‑currency revenue of $220–$228 million (≈8–12% growth on FY'26), gross profit margin of 74–76% (reflecting a ~12.5% tariff headwind and higher freight), and operating expenses of $156–$163 million (with the majority of the OpEx step‑up funding the CORIS commercial launch); CORIS is expected to deliver initial revenues in the low single‑digit millions, the company announced an additional on‑market buyback of up to $40 million (after completing $20 million in FY'26) and reiterated that trophon will continue to drive operating leverage and cash (trophon‑only EBIT FY'26: ~$50.6M reported / $56.5M cc). They also outlined CORIS unit economics: capital pricing 3–5× trophon, ~10 cycles per unit per day (3–4× trophon), price per cycle 4–6× trophon and higher expected service take‑rates (80–100% vs trophon’s ~55–60%).
Nanosonics Limited Peers Comparison
Overall Rating
AU:ANN72Outperform
AU:PNV69Neutral
AU:CSX50Neutral
AU:TRJ46Neutral
AU:PGC43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:ANN | 72Outperform | AUD 6.34B | 21.90 | 10.52% | 2.10% | 1.90% | 99.19% |
| AU:PNV | 69Neutral | AUD 625.21M | 85.38 | 8.45% | ― | 12.94% | -44.50% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:CSX | 50Neutral | AUD 35.72M | -29.22 | -6.27% | ― | 0.29% | -148.39% |
| AU:TRJ | 46Neutral | AUD 38.22M | -62.50 | -0.62% | ― | -3.05% | 86.01% |
| AU:PGC | 43Neutral | AUD 256.57M | -16.14 | -5.34% | ― | 1.84% | -178.23% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:OQS | Nanosonics Limited | 1.84 | -0.60 | -24.59% | |
| AU:ANN | Ansell Limited | 45.44 | 10.35 | 29.50% | |
| AU:PNV | Polynovo Limited | 0.91 | -0.39 | -29.84% | |
| AU:PGC | Paragon Care Limited | 0.15 | -0.17 | -51.56% | |
| AU:TRJ | Trajan Group Holdings Ltd | 0.25 | -0.54 | -68.15% | |
| AU:CSX | CleanSpace Holdings Ltd. | 0.45 | -0.27 | -37.50% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.